<DOC>
	<DOCNO>NCT00376103</DOCNO>
	<brief_summary>The purpose study determine treatment related toxicity , tumor response , progression-free survival quality life newly diagnose Glioblastoma Multiforme ( GBM ) patient undergo combination surgical resection , brachytherapy external beam radiation concomitant temozolomide , follow adjuvant temozolomide .</brief_summary>
	<brief_title>Radiation Boost Newly Diagnosed Glioblastoma Multiforme</brief_title>
	<detailed_description>The study design multi-centered non-randomized . Patients newly diagnose GBM undergoing initial surgical resection candidate study . Eligible patient undergo surgical resection within 30 day diagnosis . Newly diagnose patient presumed diagnosis GBM undergo surgery maximal resection . After frozen section diagnosis GBM confirm , GliaSite® place tumor cavity . After patient recovers surgery , radiation therapy ( 60 Gy 1 cm ) deliver via GliaSite® . Radiation therapy GliaSite® initiate within 21 day surgery . Concomitant temozolomide ( 75 mg/m2/d ) start 2 day prior radiation therapy GliaSite® continue total 7 day . Within 21 day follow radiation therapy GliaSite® , external beam radiation therapy ( 60 Gy 30 fraction ) initiate . Concomitant temozolomide ( 75 mg/m2/d ) start day 1 external beam radiation therapy continue external beam radiation therapy interval , end last day radiation . Four week ( +/- 2 day ) completion external beam radiation therapy , temozolomide ( 150 mg/m2/d ) 5 day every 28 day initiate one cycle . At start cycle 2 , dose escalate 200 mg/m2/d , CTC non-hematological toxicity cycle 1 Grade &lt; 2 ( except alopecia , nausea vomit ) . This continue total 12 cycle , unless disease progression severe myelosuppression note .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>Newly diagnose , unifocal , unilateral , supratentorial lesion see MRI suspicious Glioblastoma Multiforme Subject must candidate surgical resection tumor mass feasible gross total resection Age 18 year old Subject must appropriate candidate receive brachytherapy temozolomide per GliaSite RTS temozolomide IFU The tumor must histopathologically confirm intraoperative frozen section final pathology Karnofsky Performance Status ( KPS ) = &gt; 70 Negative pregnancy test female childbearing age surgically sterilize Male female subject agree use acceptable birth control method receive treatment ( surgically sterile ) Life expectancy &gt; 3 month Adequate laboratory result : ANC = &gt; 1.5 x 109/L . Platelets = &gt; 100 x 109/L Subject legal representative must provide informed consent HIPAA authorization prior surgery Prior use temozolomide Presence history severe hepatic renal impairment Subject tolerate temozolomide therapy due NPO status intractable nausea vomit Subject prior intracranial malignancy Major medical illness psychiatric impairment investigator opinion prevent administration completion protocol therapy Subject pacemaker MRI noncompatible metal body Previous radiation head/neck brain Pregnant lactate woman Patient allergy iodine and/or dacarbazine Creatinine &gt; 1.5x upper limit normal ( ULN ) , AST &gt; 3x ULN Chemotherapy within last 6 month Residual tumor &gt; 1 cm ( single dimension ) baseline MRI scan ( T1 postgadolinium image ) Balloon surface within 1 cm critical structure ( brain stem , midbrain , optic chiasm ) baseline MRI scan</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Brain Tumor</keyword>
	<keyword>GBM</keyword>
	<keyword>Glioblastoma Multiforme</keyword>
	<keyword>Glioblastoma</keyword>
	<keyword>Brachytherapy</keyword>
	<keyword>Temozolomide</keyword>
	<keyword>Temodar</keyword>
</DOC>